Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Philip Morris International Inc. (PM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Philip Morris International Inc. — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.02B), while Philip Morris International Inc. trades at $176.88 (market cap $280.84B). The key difference: Philip Morris International Inc. is far larger — about 35× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Philip Morris International Inc. pays a 3.26% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | PM | |
|---|---|---|
Market Cap | $8.02B | $280.84B |
Sector | Health | Consumer Staples |
52-Week High | $339.75 | $191.86 |
52-Week Low | $241.71 | $144.33 |
Enterprise Value | $7.84B | $327.33B |
Dividend Yield | — | 3.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Philip Morris International (PM) trades at $175.95, down 3.12% on the day, amid a recent profit forecast revision. The stock shows a bullish technical signal with key support at $175 and resistance at $183. Fundamentally, the company reported strong 2025 results with $40.65B revenue and $11.35B net income, though a $500M impairment charge and cost pressures prompted a lowered 2026 outlook. Analyst sentiment remains positive with a $194 consensus price target and 68% buy ratings.
The outlook is cautiously optimistic; earnings growth and the IQOS brand strength offer upside, but regulatory risks and illicit market pressures pose challenges. The current price presents a potential entry point below the analyst target, though investors must weigh margin pressures from energy costs and currency swings noted in recent company guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →
